Jp Iii Llckkr Partners Iii,... Net Worth

The estimated Net Worth of Jp Iii Llckkr Partners Iii,... is at least 368 百万$ dollars as of 8 March 2013. Jp Iii owns over 3,750,000 units of Jazz Pharmaceuticals plc stock worth over 829,265$ and over the last 13 years Jp sold JAZZ stock worth over 367,230,000$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jp Iii JAZZ stock SEC Form 4 insiders trading

Jp has made over 2 trades of the Jazz Pharmaceuticals plc stock since 2012, according to the Form 4 filled with the SEC. Most recently Jp sold 3,750,000 units of JAZZ stock worth 218,550,000$ on 8 March 2013.

The largest trade Jp's ever made was selling 3,750,000 units of Jazz Pharmaceuticals plc stock on 8 March 2013 worth over 218,550,000$. On average, Jp trades about 2,250,000 units every 121 days since 2012. As of 8 March 2013 Jp still owns at least 7,888 units of Jazz Pharmaceuticals plc stock.

You can see the complete history of Jp Iii stock trades at the bottom of the page.

Insiders trading at Jazz Pharmaceuticals plc

Over the last 17 years, insiders at Jazz Pharmaceuticals plc have traded over 1,513,676,247$ worth of Jazz Pharmaceuticals plc stock and bought 1,319,315 units worth 25,188,964$ . The most active insiders traders include Michael W Michelson、Patrick G Enright、Jp Iii Llckkr Partners Iii,.... On average, Jazz Pharmaceuticals plc executives and independent directors trade stock every 11 days with the average trade being worth of 5,162,934$. The most recent stock trade was executed by Mary Elizabeth Henderson on 6 September 2024, trading 1,410 units of JAZZ stock currently worth 152,703$.

What does Jazz Pharmaceuticals plc do?

jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni

Complete history of Jp Iii stock trades at Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc executives and stock owners

Jazz Pharmaceuticals plc executives and other stock owners filed with the SEC include:

• Bruce Cozadd,
  Chairman of the Board, Chief Executive Officer
• Daniel Swisher,
  President, Chief Operating Officer
• Robert Iannone,
  Executive Vice President, Research and Development
• Neena Patil,
  Senior Vice President, General Counsel
• Bruce C. Cozadd,
  Co-Founder, Chairman & CEO
• Daniel N. Swisher Jr.,
  Pres
• Anne O'Riordan,
  Independent Director
• Dr. Robert Iannone M.D.,
  Exec. VP of R&D and Chief Medical Officer
• Renee D. Gala,
  Exec. VP & CFO
• Kim Sablich,
  Exec. VP & GM of North America
• Rick Winningham,
  Independent Director
• Heather McSharry,
  Independent Director
• Peter Gray,
  Independent Director
• Norbert Riedel,
  Independent Director
• Patrick Enright,
  Independent Director
• Catherine Sohn,
  Independent Director
• Elmar Schnee,
  Independent Director
• Seamus Mulligan,
  Independent Director
• Kenneth O'Keefe,
  Independent Director
• Paul Berns,
  Independent Director
• Diane Schrick,
  Senior Director, Investor Relations
• Patricia Carr,
  Vice President, Finance and Principal Accounting Officer
• Samantha Pearce,
  Senior Vice President, Europe and Rest of World
• Finbar Larkin,
  Senior Vice President - Technical Operations
• Kimberly Sablich,
  Executive Vice President, General Manager - North America
• Renee Gala,
  Chief Financial Officer, Executive Vice President
• Neena M. Patil J.D.,
  Chief Legal Officer and Sr. VP of Legal & Corp. Affairs
• Andrea N. Flynn,
  VP & Head of Investor Relations
• Dr. Finbar Larkin Ph.D.,
  Sr. VP of Technical Operations
• Patricia Carr,
  VP of Fin. & Principal Accounting Officer
• Christopher John Tovey,
  Exec. VP, COO and MD of Europe & International
• Paul Treacy,
  SVP, Technical Operations
• Suzanne Sawochka Hooper,
  EVP and General Counsel
• Karen L. Smith,
  Global Head of R&D and CMO
• Karen J Wilson,
  VP of Finance & PAO
• Russell J. Cox,
  SVP, Sales and Marketing
• Iain Mc Gill,
  Head of EUSA Int'l & SVP
• Matthew P. Young,
  SVP & CFO
• Michael Patrick Miller,
  EVP, US Commercial
• Jennifer E. Cook,
  Director
• Mark Douglas Smith,
  Director
• Jp Llckkr Jp Iii Llckkr Iii...,
  
• Bryan C Cressey,
  Director
• Alan Sebulsky,
  Director
• Kathryn E Falberg,
  SVP and CFO
• Paul Egolkin Perryhuth Joha...,
  
• Michael W Michelson,
  Director
• Samuel D Colella,
  Director
• Financial Holdings Iii, Llc...,
  
• Group Holdings L.P.Kkr Grou...,
  
• Matthew K Fust,
  Senior Vice President & CFO
• Jeffrey K Tobias,
  EVP, Research & Dev and CMO
• Fintan Keegan,
  EVP, Technical Operations
• Cressey Equity Partners Inc...,
  
• Mark G. Eller,
  SVP, Research & Clinical Dev.
• James C Momtazee,
  Director
• Jp Iii Llckkr Partners Iii,...,
  
• Fund Holdings L.P.Kkr Jp Ll...,
  
• Michael A. Des Jardin,
  SVP, Product Development
• Nathaniel M Zilkha,
  Director
• Joan Colligan,
  Principal Accounting Officer
• Janne Lt Wissel,
  Senior VP of Development
• James B Tananbaum,
  Director
• Samuel R Saks,
  Chief Executive Officer
• Robert M Myers,
  President
• E Alexander Albert,
  Director
• Jp Llckkr Jp Iii Llckkr Iii...,
  
• Paul Ehuth Johannes Pfisher...,
  
• Michael W Janetschek Willia...,
  
• Carol A Gamble,
  SVP, GC and Corporate Secty
• Management Llcmignone Rober...,
  
• Henry Rroberts George Rgree...,
  
• Michael Wkkr Financial Hold...,
  
• Paul Ehuth Johannes Pfisher...,
  
• Patel Jaimin,
  Director
• Michael Wkkr Financial Hold...,
  
• Kim Sablich,
  EVP, GM of U.S.
• Mary Elizabeth Henderson,
  SVP, Technical Operations
• Christopher J. Tovey,
  EVP, COO & Managing Director E
• Laura Hamill,
  Director
• Patrick Kennedy,
  Director
• Philip L Johnson,
  EVP & Chief Financial Officer